CIMPRESS plc CMPR
Nasdaq · XNAS · stock · Commercial Printing
Chart by TradingView
5/9
Piotroski F — financial health
0.05
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $3.4B | $15.0M | — | $209.0M | -$583.5M |
| 2024 | $3.3B | $173.7M | — | $295.8M | -$550.1M |
| 2023 | $3.1B | -$186.0M | — | $76.5M | -$623.1M |
| 2022 | $2.9B | -$54.3M | — | $165.5M | -$494.9M |
| 2021 | $2.6B | -$85.2M | — | $226.7M | -$449.4M |
| 2020 | $2.5B | $83.4M | — | $288.0M | -$407.5M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.05 (distress)
- Working capital / assets -0.13
- Retained earnings / assets 0.114
- EBIT / assets 0.115
- Equity / liabilities -0.23
Source: SEC EDGAR filings · CIK 0001262976 · as of 2025-06-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.